Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Precision BioSciences, Inc. DTIL

Healthcare — Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.03
Total sells
0.47
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — 3 — — — — — — — — —
Sell — 3 — 4 4 — — — — — — —
Insider Ownership
7.68%

Capital & Financial Ratios

Market Cap
184.10
Revenue
45.07
Net Income
(52.73)
Free Cash Flow
(52.32)
Net Debt
(65.13)
Current Ratio
12.82
Debt/Equity
0.50
P/E ratio
0.00
P/S ratio
3.79
P/B ratio
3.77
Past 5Y EPS Growth
7.97%
This Y EPS Growth
(0.96%)
Next Y EPS Growth
20.98%
Next 5Y EPS Growth
17.58%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 116.68 86.31 115.59 87.55
Receivables 0.90 0.23 — —
Inventory — — — —
Other 0.91 2.01 0.05 0.01
136.36 94.99 118.74 91.55
2023 2024 2025 Q'26
Payables 2.97 1.31 0.30 0.83
ST’ Debt — — — —
Other 2.39 0.99 0.65 0.59
49.99 14.98 8.91 7.14
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 10.84 — — —
—
’25 0.03 0.02 0.01 34.20
34.26
’24 17.58 49.90 0.58 0.64
68.70
’23 8.78 19.79 13.12 7.04
48.73
’22 3.32 3.82 7.36 10.60
25.10
’21 16.35 68.81 24.04 6.34
115.53
’20 7.00 1.08 7.36 8.85
24.29
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (11.94) (13.44) — —
—
’25 (19.05) (20.27) (15.27) (11.25)
(65.84)
’24 (18.98) (14.87) (5.91) (18.68)
(58.44)
’23 (31.46) (21.13) (23.09) (8.42)
(84.11)
’22 (28.87) (24.22) 29.19 (21.84)
(45.75)
’21 68.07 (31.34) (23.90) (23.68)
(10.85)
’20 (25.91) (25.80) (22.22) (13.45)
(87.39)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (12.05) (13.44) — —
—
’25 (19.37) (20.28) (15.25) (11.57)
(66.48)
’24 (19.01) (14.90) (5.98) (18.78)
(58.66)
’23 (32.18) (22.19) (23.53) (8.38)
(86.28)
’22 (29.69) (25.00) 28.10 (22.47)
(49.07)
’21 66.95 (33.03) (25.39) (25.19)
(16.66)
’20 (27.01) (27.59) (23.27) (14.55)
(92.42)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.75) (1.26) — —
—
’25 (2.21) (2.13) (1.84) 1.05
(3.56)
’24 1.70 4.67 (2.25) (2.22)
1.04
’23 (6.91) (3.00) (2.10) (4.06)
(15.96)
’22 (13.81) (13.81) (6.61) (7.81)
(38.14)
’21 (9.91) 10.81 (5.71) (11.41)
(15.62)
’20 (15.62) (18.92) (15.01) (13.21)
(62.76)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 28.50 8.25 3.61 4.02 — — —
Low Price
— — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 235.50 43.50 19.43 8.82 — — —
High Price
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 198 109 108 68 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.45 0.64 0.50 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25.10 48.73 68.70 34.26 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (72.91) (42.53) 7.17 (46.61) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (290.50%) (87.28%) 10.43% (136.03%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (111.64) (61.32) 7.17 (45.72) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.65 7.74 3.88 2.07 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.57 12.69 10.05 2.67 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (38.14) (15.96) 1.05 (3.56) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.62) (21.90) (8.55) (5.13) — — —
Cash Flow/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.13) (0.57) (0.03) (0.05) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.75) (22.46) (8.58) (5.18) — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 20.63 4.91 8.25 7.19 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.93 3.84 6.83 12.83 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 1.97 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.10 0.88 0.38 1.56 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.70 2.26 0.46 0.58 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.49) (0.96) (0.21) (0.47) ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.27 0.54 0.24 0.24 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.75) (84.11) (58.44) (65.84) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.32) (2.17) (0.21) (0.63) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (49.07) (86.28) (58.66) (66.48) ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 139.44 86.37 80.01 109.83 — — —
Working Cap'
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 24.26 — 22.32 22.40 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (165.32) (116.68) (63.99) (93.18) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 60.43 18.86 56.39 92.25 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (49.65%) (30.82%) 4.84% (31.45%) ‡‡‡‡‡ — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (147.28%) (154.66%) 19.05% (61.52%) ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Precision BioSciences (DTIL), a clinical-stage biotech harnessing its ARCUS gene-editing platform for liver diseases and oncology, exemplifies sector volatility—plunging over 99% from 2019 IPO highs amid hype, pandemics, and funding crunches. Yet, 2024 marked a rare profitability milestone, with revenues surging 41% to $68.7 million, swinging net income positive at $7.2 million (EPS $1.05) and ROE to 19.1%, fueled by milestone payments from partnerships like Gilead and Servier. This masked a lumpy business model reliant on one-off deals rather than steady sales, with gross margins at 100% but persistent cash burns.

Looking ahead, analyst forecasts warn of a stark reversal: 2025 revenues cratering 87% to $9.1 million and deep losses resuming (EPS -$6.14), highlighting pipeline delays and milestone droughts. The balance sheet offers some solace—negative net debt of -$64 million and $80 million working capital provide a 2-3 year runway—but risks abound: historical dilution, insider selling outpacing director buys, and biotech’s 90% clinical failure rate. Trading at depressed multiples like 0.46x PB and negative EV/sales, the stock screams undervaluation, yet analysts’ 400-1,500% upside targets clash with fundamentals.

For risk-averse investors, DTIL is a high-conviction spec play tied to catalysts like HBV and NASH trials, best limited to 1-2% portfolio exposure until Q1 2026 earnings clarify the revenue cliff. Dive into the full analysis for revenue breakdowns, insider details, and pragmatic risk-reward math.

Read full commentary →

Precision BioSciences, Inc. (DTIL) Latest News

News by impact score

Fine-tune

24 Aug

4 , 6:01 AM
Precision BioSciences has started dosing in its Phase 1/2 FUNCTION-DMD study. Phase 1/2 dosing start marks a key clinical milestone that can materially advance the company's DMD program and investor outlook.

6 Aug

3 , 7:01 AM
Precision BioSciences reported second quarter 2026 financial results and issued a business update. Quarterly results and business updates typically move near-term sentiment and valuation for the company.

21 May

3 Business Wire, 7:01 AM
Precision BioSciences will host an investor webcast to discuss late-breaking PBGENE-HBV data from the ELIMINATE-B trial presented at the European Association for the Study of the Liver Congress 2026. Late-breaking HBV gene editing trial data presentation at a major medical congress plus dedicated investor webcast can moderately shift near-term sentiment and pipeline visibility.

14 May

4 , 7:01 AM
Precision BioSciences presented new preclinical data at the American Society of Gene & Cell Therapy 2026 Annual Meeting supporting advancement of PBGENE-DMD into clinical trials. Positive preclinical data for PBGENE-DMD enables clinical progression, marking a pivotal pipeline milestone likely to drive significant investor interest and valuation uplift for DTIL.

13 May

3 Simply Wall St., 7:07 AM
Analysts made a notable bullish upgrade to forecasts for Precision BioSciences, Inc. (NASDAQ:DTIL). Notable analyst forecast upgrades moderately boost market sentiment and expectations for financial performance.

5 May

4 Business Wire, 7:01 AM
Precision BioSciences, Inc. (DTIL) reported first quarter 2026 financial results and provided a business update. Quarterly financial results and business updates represent major disclosures that can significantly alter investor sentiment and the company's stock trajectory.

3 Zacks, 8:25 AM
Precision BioSciences (DTIL) reported a Q1 net loss but topped revenue estimates. Q1 revenue beat despite net loss moderately affects financial performance and market sentiment.

29 Apr

4 Business Wire, 7:01 AM
Precision BioSciences activates first clinical trial site and begins patient enrollment in Phase 1/2 FUNCTION-DMD study for Duchenne muscular dystrophy gene therapy. Starting patient enrollment in a Phase 1/2 trial advances the gene editing pipeline for DMD, potentially boosting investor sentiment and stock performance.

28 Apr

3 Business Wire, 7:01 AM
Precision BioSciences, Inc. (DTIL) announces an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting. Oral presentation at major gene therapy conference signals research progress and visibility, moderately influencing investor sentiment without transformative details.

22 Apr

3 Business Wire, 7:01 AM
Precision BioSciences, Inc. (DTIL) announces late-breaking poster presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026. Late-breaking poster at major liver congress highlights progress in PBGENE-HBV, potentially influencing investor sentiment and competitive positioning.

15 Apr

4 Business Wire, 7:01 AM
Precision BioSciences expands ELIMINATE-B trial after Clinical Trial Application approvals in two European countries. Trial expansion following European regulatory approvals accelerates Precision BioSciences' clinical pipeline and positively influences market performance.

12 Mar

4 Zacks, 8:15 AM
Precision BioSciences, Inc. (DTIL) surpassed Q4 earnings and revenue estimates. Surpassing Q4 earnings and revenue estimates boosts investor sentiment and stock performance significantly.

4 Business Wire, 7:00 AM
Precision BioSciences, Inc. (DTIL) reported fourth quarter and fiscal year 2025 financial results, highlighting key metrics and cash position, alongside a business update on pipeline progress including in vivo gene editing programs and strategic advancements. Quarterly and annual financial results with pipeline business updates represent major strategic disclosures that significantly influence investor sentiment, stock volatility, and future performance.

3 Associated Press Finance, 7:15 AM
Precision BioSciences, Inc. (DTIL) released Q4 earnings snapshot reporting key quarterly financial results including revenue, net loss, and EPS compared to expectations. Quarterly earnings snapshot affects short-term financial performance and stock sentiment but represents routine reporting without transformative developments.

11 Mar

4 , 7:01 AM
Precision BioSciences, Inc. (DTIL) received U.S. patent allowances covering its PBGENE-HBV program, which uses gene editing to target chronic hepatitis B virus with ARCUS nuclease for potential functional cures. Patent allowances bolster IP protection for the core PBGENE-HBV program, enhancing DTIL's competitive edge in hepatitis B treatments and boosting investor confidence.

10 Mar

3 Business Wire, 7:01 AM
Precision BioSciences presented preclinical PBGENE-DMD data at the Muscular Dystrophy Association Clinical & Scientific Conference 2026, demonstrating durable dystrophin expression and functional benefits. Preclinical DMD gene therapy data showing durable dystrophin expression offers moderate pipeline validation and potential sentiment boost without clinical proof.

9 Mar

4 Business Wire, 7:01 AM
Precision BioSciences (DTIL) received FDA Fast Track Designation for PBGENE-DMD, its investigational gene editing therapy for Duchenne Muscular Dystrophy, accelerating development and review. The company announced an investor event to discuss its DMD program. FDA Fast Track Designation for PBGENE-DMD accelerates clinical development and regulatory review, significantly enhancing DTIL's pipeline value and investor sentiment.

8 Mar

4 Simply Wall St., 4:11 PM
Investors react to TG Therapeutics (TGTX) adding Azer-cel milestone to its multiple sclerosis (MS) portfolio. Azer-cel milestone integration into TGTX's MS portfolio signals potential revenue triggers and indication expansion for Precision BioSciences (DTIL).

4 Simply Wall St., 2:11 PM
Precision BioSciences' Azer Cel achieves milestone, expanding TG Therapeutics' autoimmune pipeline and bolstering its valuation narrative. Azer Cel milestone enhances DTIL's partnership revenues and market positioning via TG Therapeutics' broadened autoimmune portfolio.

2 Mar

4 Business Wire, 7:01 AM
Precision BioSciences, Inc. (DTIL) received $7.5 million from TG Therapeutics for achieving a clinical milestone with Azer-cel in multiple sclerosis. $7.5M non-dilutive funding validates Azer-cel progress in MS and bolsters DTIL's cash position for pipeline advancement.

11 Feb

4 Business Wire, 7:01 AM
Precision BioSciences, Inc. has received U.S. FDA clearance for its Investigational New Drug Application for PBGENE-DMD, a first-in-class gene therapy aimed at treating Duchenne Muscular Dystrophy. This marks a significant milestone for the company as it advances its innovative treatment into clinical trials, potentially addressing a critical unmet need in the rare disease space. FDA clearance for a first-in-class therapy is a significant strategic move that could enhance the company's market position and investor sentiment.

12 Jan

4 Business Wire, 7:01 AM
Precision BioSciences, Inc. has outlined its strategic priorities for 2026, focusing on the advancement of its clinical-stage programs, specifically PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. The company aims to enhance its pipeline and drive innovation in these therapeutic areas, indicating a commitment to addressing significant unmet medical needs. The strategic focus on advancing key clinical-stage programs is likely to significantly impact the company's future performance and investor sentiment.

19 Nov

4 Business WireClinical Trials ArenaGuruFocus.comMotley FoolClinical Trials ArenaGuruFocus.comMT NewswiresZacks, 7:01 AM
Precision BioSciences, Inc. announced the presentation of clinical data from the ELIMINATE-B trial at the HEP-DART 2025 conference. This trial focuses on evaluating the efficacy and safety of their innovative therapies, which could have significant implications for treatment options in the relevant medical field. The presentation of clinical data from a key trial could significantly influence investor sentiment and the company's strategic direction.

10 Nov

4 Business Wire, 5:21 PM
Precision BioSciences, Inc. presented late-breaking Phase 1 data for PBGENE-HBV at AASLD The Liver Meeting®, demonstrating safety, tolerability, and cumulative, dose-dependent antiviral activity in the first three cohorts of the trial. The positive Phase 1 data could significantly enhance the company's product pipeline and investor sentiment.

3 Business Wire, 6:12 PM
Precision BioSciences, Inc. announced a $75 million offering of common stock, pre-funded warrants, and warrants. The offering aims to strengthen the company's financial position and support its ongoing development initiatives. The securities will be offered through a registered direct offering, with proceeds intended for general corporate purposes, including research and development activities. The capital raise is expected to provide necessary funding for ongoing projects, which may influence financial performance but is not a transformative event.

3 Nov

3 Associated Press Finance, 7:10 AM
Precision BioSciences, Inc. reported its Q3 earnings, highlighting key financial metrics and developments in its operations. The company continues to focus on advancing its gene editing technology and expanding its pipeline of therapies. Despite challenges in the market, Precision BioSciences remains committed to its strategic goals and innovation in the biotech sector. The earnings report indicates moderate financial performance and ongoing strategic initiatives that may influence the company's competitive positioning.

3 Business Wire, 7:01 AM
Precision BioSciences, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its business operations. The company provided updates on its ongoing projects and strategic initiatives, reflecting its focus on advancing its gene-editing technologies and expanding its market presence. Financial performance indicators showed trends that may influence future growth and investor sentiment. The financial results and business updates indicate moderate influences on the company's performance and market positioning.

31 Oct

3 Simply Wall St., 6:41 AM
Precision BioSciences, Inc. (NASDAQ:DTIL) experienced a significant increase in its stock value, climbing 24% last week, which positively impacted its one-year returns. This surge is likely to please institutional investors who have stakes in the company, reflecting a favorable market sentiment towards its performance. The recent stock gain indicates a moderately noticeable influence on investor sentiment and potential financial performance.

16 Oct

3 Zacks, 8:05 AM
Precision BioSciences, Inc. (DTIL) experienced an 11.1% increase in stock price, raising questions about the sustainability of this upward trend. Investors are analyzing the factors contributing to this surge and whether it reflects a lasting improvement in the company's market position or is merely a short-term fluctuation. The stock price increase indicates moderate investor interest, but it is unclear if this will lead to sustained financial performance improvements.

14 Oct

4 Business Wire, 7:01 AM
Precision BioSciences, Inc. announced a late-breaking oral presentation for its PBGENE-HBV program at the AASLD The Liver Meeting® 2025. This presentation highlights the company's advancements in gene editing technology aimed at treating hepatitis B virus infections, showcasing its commitment to addressing significant unmet medical needs in liver disease. The presentation at a major medical conference indicates significant progress in a key therapeutic area, potentially enhancing the company's market position and investor interest.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us